Summary of findings: monoclonal antibody KB001‐A vs placebo
Number experiencing adverse effects · children (12 or over) and adults with cystic fibrosis and lung infection
It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes adverse events number of participants experiencing adverse events compared with placebo (very low certainty).
1 finding from 1 review
- Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes onlyRR 1.3 [0.9, 1.87]2 studies · 196 participantsVery low